We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Biomarker Predicts Risk of Preterm Birth Earlier

By LabMedica International staff writers
Posted on 26 Jan 2016
Print article
Image: Fetal fibronectin is a “glue-like” protein that holds the developing baby in the womb (Photo courtesy of Hologic Inc.).
Image: Fetal fibronectin is a “glue-like” protein that holds the developing baby in the womb (Photo courtesy of Hologic Inc.).
Image: The fetal fibronectin test system for predicting preterm labor risk (Photo courtesy of Hologic Inc.).
Image: The fetal fibronectin test system for predicting preterm labor risk (Photo courtesy of Hologic Inc.).
A standard biomarker test offered earlier in pregnancy could potentially help doctors to better identify women at risk of giving birth prematurely, thus enabling health services to focus treatments on women at highest risk.

A number of factors are used to determine if a woman is at risk of giving birth prematurely, including a history of preterm births or late miscarriages. Two further factors which clinicians normally consider are the length of cervix and levels of a biomarker found in vaginal fluid known as fetal fibronectin.

Scientists at King's College London (London, UK) compared measurements of a new fetal fibronectin test in the cervicovaginal fluid of women at 18 to 21 weeks of gestation with measurements made at 22 to 27 weeks of gestation, to see which time period offered the best prediction of spontaneous preterm birth. They also explored whether using a low (10 ng/mL) and high (200 ng/mL) threshold would more accurately classify a women's risk of giving birth prematurely.

Fetal fibronectin was measured using Hologic 10Q system (Hologic; Marlborough, MA, USA). Of the 898 high risk women followed in the study, 8.7% delivered spontaneously before 34 weeks of gestation and only 3.8% of women with concentrations less than 10 ng/mL (tested at 18–21 weeks) delivered before 34 weeks of gestation, a similar rate to that expected in a normal pregnancy. This compared to 2.9% in those tested later (22–27 weeks). In those woman over 200 ng/mL, similar proportions delivered after 34 weeks whether tested early or late (39% versus 43%).

The authors concluded that measuring fetal fibronectin at 18–21 weeks pregnancy appears to offer a similar predictive value to measurements at 22–27 weeks. For both the early and standard tests, there was a noticeable increase in relative risk between the lowest and highest thresholds used in the study. Combining cervical length with the biomarker test was found to improve the diagnostic accuracy further. Low fibronectin concentrations are associated with spontaneous preterm birthrates approaching population background levels.

Andrew A. Shennan, MD, a professor of Obstetrics and lead author of the study, said, “The aim of our study was to find better ways of establishing the risk of women giving birth prematurely in early pregnancy, to enable us to focus on the women most likely to benefit from earlier intervention and close monitoring during pregnancy. Instead of relying on the traditional single threshold later in pregnancy we now can more accurately identify those likely to be normal and those most in need of early interventions, from the first half of pregnancy.” The study was published on January 7, 2016, in the journal Obstetrics and Gynecology.

Related Links:

King's College London
Hologic


New
Gold Member
Strep Pneumoniae Rapid Test
Strep Pneumoniae (6503 – 6573)
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Centrifuge
Mikro 200
New
Autoimmune Disease Test
Anti-Centromere B ELISA Test

Print article

Channels

Molecular Diagnostics

view channel
Image: The kit includes a container with a film, a compact optical device for attaching a smartphone, and a diagnostic app (Photo courtesy of KIST)

Urine-Based Bladder Cancer Diagnostic Kit to Reduce Need for Unnecessary Cystoscopies

Bladder cancer has a high cure rate of over 90% when detected early, but it is characterized by a recurrence rate of 70%, which requires continuous monitoring. Late-stage detection often results in major... Read more

Microbiology

view channel
Image: The QIAstat-Dx mini gastrointestinal panel has secured U.S. clearance to support year-round outpatient care (Photo courtesy of QIAGEN)

Syndromic Panel Provides Fast Answers for Outpatient Diagnosis of Gastrointestinal Conditions

Acute infectious gastroenteritis is a major cause of outpatient visits and hospitalizations in the U.S., with over 179 million cases estimated annually. Now, a new gastrointestinal panel designed to provide... Read more

Pathology

view channel
Image: The AI tool can search through data and histology images for much more precise information on cancer treatment effectiveness (Photo courtesy of Shutterstock)

AI Tool Analyzes 30K Data Points Per Medical Imaging Pixel in Cancer Search

A new artificial intelligence (AI)-powered tool can detect cell-level characteristics of cancer by analyzing data from very small tissue samples, some as tiny as 400 square micrometers, equivalent to the... Read more

Technology

view channel
Image: Human tear film protein sampling methods (Photo courtesy of Clinical Proteomics. 2024 Mar 13;21:23. doi: 10.1186/s12014-024-09475-8)

New Lens Method Analyzes Tears for Early Disease Detection

Bodily fluids, including tears and saliva, carry proteins that are released from different parts of the body. The presence of specific proteins in these biofluids can be a sign of health issues.... Read more

Industry

view channel
Image: The game-changing immunoassay diagnostics platform delivers results from whole blood sample in 10 minutes (Photo courtesy of SpinChip)

bioMérieux Acquires Norwegian Immunoassay Start-Up SpinChip Diagnostics

bioMérieux (Marcy l’Étoile, France) has agreed to acquire SpinChip Diagnostics (Oslo, Norway), the developer of a game-changing immunoassay diagnostics platform. The small benchtop analyzer is well adapted... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.